nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Erythema—Dactinomycin—muscle cancer	0.00422	0.00422	CcSEcCtD
Tobramycin—Delirium—Doxorubicin—muscle cancer	0.00421	0.00421	CcSEcCtD
Tobramycin—Bone disorder—Doxorubicin—muscle cancer	0.00401	0.00401	CcSEcCtD
Tobramycin—Hypocalcaemia—Doxorubicin—muscle cancer	0.00396	0.00396	CcSEcCtD
Tobramycin—Cough increased—Doxorubicin—muscle cancer	0.00396	0.00396	CcSEcCtD
Tobramycin—Oliguria—Doxorubicin—muscle cancer	0.00393	0.00393	CcSEcCtD
Tobramycin—Lacrimation increased—Doxorubicin—muscle cancer	0.00393	0.00393	CcSEcCtD
Tobramycin—Angiopathy—Vincristine—muscle cancer	0.00393	0.00393	CcSEcCtD
Tobramycin—Ill-defined disorder—Dactinomycin—muscle cancer	0.00391	0.00391	CcSEcCtD
Tobramycin—Infestation—Etoposide—muscle cancer	0.00391	0.00391	CcSEcCtD
Tobramycin—Infestation NOS—Etoposide—muscle cancer	0.00391	0.00391	CcSEcCtD
Tobramycin—Mediastinal disorder—Vincristine—muscle cancer	0.0039	0.0039	CcSEcCtD
Tobramycin—Anaemia—Dactinomycin—muscle cancer	0.0039	0.0039	CcSEcCtD
Tobramycin—Renal failure—Etoposide—muscle cancer	0.00384	0.00384	CcSEcCtD
Tobramycin—Blood bilirubin increased—Doxorubicin—muscle cancer	0.00383	0.00383	CcSEcCtD
Tobramycin—Neuropathy peripheral—Etoposide—muscle cancer	0.00383	0.00383	CcSEcCtD
Tobramycin—Stomatitis—Etoposide—muscle cancer	0.00381	0.00381	CcSEcCtD
Tobramycin—Creatinine increased—Doxorubicin—muscle cancer	0.0038	0.0038	CcSEcCtD
Tobramycin—Malaise—Dactinomycin—muscle cancer	0.0038	0.0038	CcSEcCtD
Tobramycin—Leukopenia—Dactinomycin—muscle cancer	0.00377	0.00377	CcSEcCtD
Tobramycin—Agranulocytosis—Etoposide—muscle cancer	0.00364	0.00364	CcSEcCtD
Tobramycin—Back pain—Vincristine—muscle cancer	0.00364	0.00364	CcSEcCtD
Tobramycin—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.00362	0.00362	CcSEcCtD
Tobramycin—Myalgia—Dactinomycin—muscle cancer	0.00359	0.00359	CcSEcCtD
Tobramycin—Discomfort—Dactinomycin—muscle cancer	0.00355	0.00355	CcSEcCtD
Tobramycin—Thrombophlebitis—Methotrexate—muscle cancer	0.00351	0.00351	CcSEcCtD
Tobramycin—Anaemia—Vincristine—muscle cancer	0.00348	0.00348	CcSEcCtD
Tobramycin—Urinary tract disorder—Etoposide—muscle cancer	0.00346	0.00346	CcSEcCtD
Tobramycin—Urethral disorder—Etoposide—muscle cancer	0.00344	0.00344	CcSEcCtD
Tobramycin—Vertigo—Vincristine—muscle cancer	0.00339	0.00339	CcSEcCtD
Tobramycin—Leukopenia—Vincristine—muscle cancer	0.00337	0.00337	CcSEcCtD
Tobramycin—Thrombocytopenia—Dactinomycin—muscle cancer	0.00337	0.00337	CcSEcCtD
Tobramycin—Dry eye—Doxorubicin—muscle cancer	0.00334	0.00334	CcSEcCtD
Tobramycin—Rash maculo-papular—Doxorubicin—muscle cancer	0.00329	0.00329	CcSEcCtD
Tobramycin—Renal failure acute—Methotrexate—muscle cancer	0.00329	0.00329	CcSEcCtD
Tobramycin—Anorexia—Dactinomycin—muscle cancer	0.00328	0.00328	CcSEcCtD
Tobramycin—Eye disorder—Etoposide—muscle cancer	0.00328	0.00328	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Methotrexate—muscle cancer	0.00322	0.00322	CcSEcCtD
Tobramycin—Myalgia—Vincristine—muscle cancer	0.00321	0.00321	CcSEcCtD
Tobramycin—Angiopathy—Etoposide—muscle cancer	0.00318	0.00318	CcSEcCtD
Tobramycin—Immune system disorder—Etoposide—muscle cancer	0.00317	0.00317	CcSEcCtD
Tobramycin—Mediastinal disorder—Etoposide—muscle cancer	0.00316	0.00316	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00314	0.00314	CcSEcCtD
Tobramycin—Lethargy—Methotrexate—muscle cancer	0.0031	0.0031	CcSEcCtD
Tobramycin—Anaphylactic shock—Vincristine—muscle cancer	0.00308	0.00308	CcSEcCtD
Tobramycin—Thrombophlebitis—Doxorubicin—muscle cancer	0.00304	0.00304	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.00302	0.00302	CcSEcCtD
Tobramycin—Nervous system disorder—Vincristine—muscle cancer	0.00302	0.00302	CcSEcCtD
Tobramycin—Thrombocytopenia—Vincristine—muscle cancer	0.00301	0.00301	CcSEcCtD
Tobramycin—Decreased appetite—Dactinomycin—muscle cancer	0.00299	0.00299	CcSEcCtD
Tobramycin—Dysgeusia—Etoposide—muscle cancer	0.00299	0.00299	CcSEcCtD
Tobramycin—Back pain—Etoposide—muscle cancer	0.00295	0.00295	CcSEcCtD
Tobramycin—Pain—Dactinomycin—muscle cancer	0.00294	0.00294	CcSEcCtD
Tobramycin—Anorexia—Vincristine—muscle cancer	0.00293	0.00293	CcSEcCtD
Tobramycin—Eye pain—Doxorubicin—muscle cancer	0.00291	0.00291	CcSEcCtD
Tobramycin—Renal failure acute—Doxorubicin—muscle cancer	0.00285	0.00285	CcSEcCtD
Tobramycin—Feeling abnormal—Dactinomycin—muscle cancer	0.00284	0.00284	CcSEcCtD
Tobramycin—Ill-defined disorder—Etoposide—muscle cancer	0.00283	0.00283	CcSEcCtD
Tobramycin—Anaemia—Etoposide—muscle cancer	0.00282	0.00282	CcSEcCtD
Tobramycin—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00281	0.00281	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Vincristine—muscle cancer	0.0028	0.0028	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.00279	0.00279	CcSEcCtD
Tobramycin—Renal impairment—Doxorubicin—muscle cancer	0.00276	0.00276	CcSEcCtD
Tobramycin—Paraesthesia—Vincristine—muscle cancer	0.00276	0.00276	CcSEcCtD
Tobramycin—Malaise—Etoposide—muscle cancer	0.00275	0.00275	CcSEcCtD
Tobramycin—Vertigo—Etoposide—muscle cancer	0.00274	0.00274	CcSEcCtD
Tobramycin—Leukopenia—Etoposide—muscle cancer	0.00273	0.00273	CcSEcCtD
Tobramycin—Abdominal pain—Dactinomycin—muscle cancer	0.00272	0.00272	CcSEcCtD
Tobramycin—Body temperature increased—Dactinomycin—muscle cancer	0.00272	0.00272	CcSEcCtD
Tobramycin—Lethargy—Doxorubicin—muscle cancer	0.00268	0.00268	CcSEcCtD
Tobramycin—Decreased appetite—Vincristine—muscle cancer	0.00267	0.00267	CcSEcCtD
Tobramycin—Cough—Etoposide—muscle cancer	0.00266	0.00266	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Vincristine—muscle cancer	0.00265	0.00265	CcSEcCtD
Tobramycin—Pain—Vincristine—muscle cancer	0.00263	0.00263	CcSEcCtD
Tobramycin—Asthma—Methotrexate—muscle cancer	0.00262	0.00262	CcSEcCtD
Tobramycin—Chest pain—Etoposide—muscle cancer	0.0026	0.0026	CcSEcCtD
Tobramycin—Eosinophilia—Methotrexate—muscle cancer	0.0026	0.0026	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00258	0.00258	CcSEcCtD
Tobramycin—Discomfort—Etoposide—muscle cancer	0.00257	0.00257	CcSEcCtD
Tobramycin—Hypersensitivity—Dactinomycin—muscle cancer	0.00254	0.00254	CcSEcCtD
Tobramycin—Gastrointestinal pain—Vincristine—muscle cancer	0.00251	0.00251	CcSEcCtD
Tobramycin—Confusional state—Etoposide—muscle cancer	0.00251	0.00251	CcSEcCtD
Tobramycin—Anaphylactic shock—Etoposide—muscle cancer	0.00249	0.00249	CcSEcCtD
Tobramycin—Asthenia—Dactinomycin—muscle cancer	0.00247	0.00247	CcSEcCtD
Tobramycin—Blood creatinine increased—Doxorubicin—muscle cancer	0.00246	0.00246	CcSEcCtD
Tobramycin—Dehydration—Doxorubicin—muscle cancer	0.00244	0.00244	CcSEcCtD
Tobramycin—Thrombocytopenia—Etoposide—muscle cancer	0.00244	0.00244	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Methotrexate—muscle cancer	0.00244	0.00244	CcSEcCtD
Tobramycin—Body temperature increased—Vincristine—muscle cancer	0.00243	0.00243	CcSEcCtD
Tobramycin—Abdominal pain—Vincristine—muscle cancer	0.00243	0.00243	CcSEcCtD
Tobramycin—Skin disorder—Etoposide—muscle cancer	0.00242	0.00242	CcSEcCtD
Tobramycin—Dry skin—Doxorubicin—muscle cancer	0.00241	0.00241	CcSEcCtD
Tobramycin—Hypokalaemia—Doxorubicin—muscle cancer	0.00239	0.00239	CcSEcCtD
Tobramycin—Anorexia—Etoposide—muscle cancer	0.00237	0.00237	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.00237	0.00237	CcSEcCtD
Tobramycin—Diarrhoea—Dactinomycin—muscle cancer	0.00235	0.00235	CcSEcCtD
Tobramycin—Infestation—Methotrexate—muscle cancer	0.00234	0.00234	CcSEcCtD
Tobramycin—Infestation NOS—Methotrexate—muscle cancer	0.00234	0.00234	CcSEcCtD
Tobramycin—Muscular weakness—Doxorubicin—muscle cancer	0.00232	0.00232	CcSEcCtD
Tobramycin—Renal failure—Methotrexate—muscle cancer	0.0023	0.0023	CcSEcCtD
Tobramycin—Stomatitis—Methotrexate—muscle cancer	0.00228	0.00228	CcSEcCtD
Tobramycin—Asthma—Doxorubicin—muscle cancer	0.00227	0.00227	CcSEcCtD
Tobramycin—Hypersensitivity—Vincristine—muscle cancer	0.00227	0.00227	CcSEcCtD
Tobramycin—Eosinophilia—Doxorubicin—muscle cancer	0.00225	0.00225	CcSEcCtD
Tobramycin—Paraesthesia—Etoposide—muscle cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Dyspnoea—Etoposide—muscle cancer	0.00222	0.00222	CcSEcCtD
Tobramycin—Epistaxis—Methotrexate—muscle cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Asthenia—Vincristine—muscle cancer	0.00221	0.00221	CcSEcCtD
Tobramycin—Vomiting—Dactinomycin—muscle cancer	0.00219	0.00219	CcSEcCtD
Tobramycin—Bronchitis—Doxorubicin—muscle cancer	0.00218	0.00218	CcSEcCtD
Tobramycin—Agranulocytosis—Methotrexate—muscle cancer	0.00218	0.00218	CcSEcCtD
Tobramycin—Rash—Dactinomycin—muscle cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Decreased appetite—Etoposide—muscle cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Etoposide—muscle cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Pain—Etoposide—muscle cancer	0.00213	0.00213	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.00211	0.00211	CcSEcCtD
Tobramycin—Diarrhoea—Vincristine—muscle cancer	0.0021	0.0021	CcSEcCtD
Tobramycin—Pharyngitis—Methotrexate—muscle cancer	0.00208	0.00208	CcSEcCtD
Tobramycin—Urinary tract disorder—Methotrexate—muscle cancer	0.00207	0.00207	CcSEcCtD
Tobramycin—Urethral disorder—Methotrexate—muscle cancer	0.00206	0.00206	CcSEcCtD
Tobramycin—Weight decreased—Doxorubicin—muscle cancer	0.00206	0.00206	CcSEcCtD
Tobramycin—Feeling abnormal—Etoposide—muscle cancer	0.00205	0.00205	CcSEcCtD
Tobramycin—Nausea—Dactinomycin—muscle cancer	0.00204	0.00204	CcSEcCtD
Tobramycin—Gastrointestinal pain—Etoposide—muscle cancer	0.00204	0.00204	CcSEcCtD
Tobramycin—Dizziness—Vincristine—muscle cancer	0.00203	0.00203	CcSEcCtD
Tobramycin—Infestation NOS—Doxorubicin—muscle cancer	0.00203	0.00203	CcSEcCtD
Tobramycin—Infestation—Doxorubicin—muscle cancer	0.00203	0.00203	CcSEcCtD
Tobramycin—Visual impairment—Methotrexate—muscle cancer	0.00202	0.00202	CcSEcCtD
Tobramycin—Renal failure—Doxorubicin—muscle cancer	0.00199	0.00199	CcSEcCtD
Tobramycin—Neuropathy peripheral—Doxorubicin—muscle cancer	0.00199	0.00199	CcSEcCtD
Tobramycin—Urticaria—Etoposide—muscle cancer	0.00198	0.00198	CcSEcCtD
Tobramycin—Stomatitis—Doxorubicin—muscle cancer	0.00197	0.00197	CcSEcCtD
Tobramycin—Abdominal pain—Etoposide—muscle cancer	0.00197	0.00197	CcSEcCtD
Tobramycin—Body temperature increased—Etoposide—muscle cancer	0.00197	0.00197	CcSEcCtD
Tobramycin—Eye disorder—Methotrexate—muscle cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Tinnitus—Methotrexate—muscle cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Vomiting—Vincristine—muscle cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Rash—Vincristine—muscle cancer	0.00194	0.00194	CcSEcCtD
Tobramycin—Dermatitis—Vincristine—muscle cancer	0.00194	0.00194	CcSEcCtD
Tobramycin—Headache—Vincristine—muscle cancer	0.00193	0.00193	CcSEcCtD
Tobramycin—Epistaxis—Doxorubicin—muscle cancer	0.00191	0.00191	CcSEcCtD
Tobramycin—Angiopathy—Methotrexate—muscle cancer	0.00191	0.00191	CcSEcCtD
Tobramycin—Sinusitis—Doxorubicin—muscle cancer	0.0019	0.0019	CcSEcCtD
Tobramycin—Immune system disorder—Methotrexate—muscle cancer	0.0019	0.0019	CcSEcCtD
Tobramycin—Mediastinal disorder—Methotrexate—muscle cancer	0.00189	0.00189	CcSEcCtD
Tobramycin—Agranulocytosis—Doxorubicin—muscle cancer	0.00189	0.00189	CcSEcCtD
Tobramycin—Hypersensitivity—Etoposide—muscle cancer	0.00184	0.00184	CcSEcCtD
Tobramycin—Erythema—Methotrexate—muscle cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Nausea—Vincristine—muscle cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Rhinitis—Doxorubicin—muscle cancer	0.00182	0.00182	CcSEcCtD
Tobramycin—Pharyngitis—Doxorubicin—muscle cancer	0.0018	0.0018	CcSEcCtD
Tobramycin—Urinary tract disorder—Doxorubicin—muscle cancer	0.0018	0.0018	CcSEcCtD
Tobramycin—Dysgeusia—Methotrexate—muscle cancer	0.00179	0.00179	CcSEcCtD
Tobramycin—Asthenia—Etoposide—muscle cancer	0.00179	0.00179	CcSEcCtD
Tobramycin—Connective tissue disorder—Doxorubicin—muscle cancer	0.00179	0.00179	CcSEcCtD
Tobramycin—Urethral disorder—Doxorubicin—muscle cancer	0.00178	0.00178	CcSEcCtD
Tobramycin—Back pain—Methotrexate—muscle cancer	0.00177	0.00177	CcSEcCtD
Tobramycin—Pruritus—Etoposide—muscle cancer	0.00176	0.00176	CcSEcCtD
Tobramycin—Visual impairment—Doxorubicin—muscle cancer	0.00175	0.00175	CcSEcCtD
Tobramycin—Vision blurred—Methotrexate—muscle cancer	0.00172	0.00172	CcSEcCtD
Tobramycin—Diarrhoea—Etoposide—muscle cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Eye disorder—Doxorubicin—muscle cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Ill-defined disorder—Methotrexate—muscle cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Tinnitus—Doxorubicin—muscle cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Anaemia—Methotrexate—muscle cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Angiopathy—Doxorubicin—muscle cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Malaise—Methotrexate—muscle cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Dizziness—Etoposide—muscle cancer	0.00165	0.00165	CcSEcCtD
Tobramycin—Immune system disorder—Doxorubicin—muscle cancer	0.00164	0.00164	CcSEcCtD
Tobramycin—Vertigo—Methotrexate—muscle cancer	0.00164	0.00164	CcSEcCtD
Tobramycin—Mediastinal disorder—Doxorubicin—muscle cancer	0.00164	0.00164	CcSEcCtD
Tobramycin—Leukopenia—Methotrexate—muscle cancer	0.00164	0.00164	CcSEcCtD
Tobramycin—Cough—Methotrexate—muscle cancer	0.0016	0.0016	CcSEcCtD
Tobramycin—Vomiting—Etoposide—muscle cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Erythema—Doxorubicin—muscle cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Rash—Etoposide—muscle cancer	0.00157	0.00157	CcSEcCtD
Tobramycin—Dermatitis—Etoposide—muscle cancer	0.00157	0.00157	CcSEcCtD
Tobramycin—Headache—Etoposide—muscle cancer	0.00156	0.00156	CcSEcCtD
Tobramycin—Myalgia—Methotrexate—muscle cancer	0.00156	0.00156	CcSEcCtD
Tobramycin—Chest pain—Methotrexate—muscle cancer	0.00156	0.00156	CcSEcCtD
Tobramycin—Dysgeusia—Doxorubicin—muscle cancer	0.00155	0.00155	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00155	0.00155	CcSEcCtD
Tobramycin—Discomfort—Methotrexate—muscle cancer	0.00154	0.00154	CcSEcCtD
Tobramycin—Back pain—Doxorubicin—muscle cancer	0.00153	0.00153	CcSEcCtD
Tobramycin—Confusional state—Methotrexate—muscle cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Anaphylactic shock—Methotrexate—muscle cancer	0.00149	0.00149	CcSEcCtD
Tobramycin—Vision blurred—Doxorubicin—muscle cancer	0.00149	0.00149	CcSEcCtD
Tobramycin—Nausea—Etoposide—muscle cancer	0.00148	0.00148	CcSEcCtD
Tobramycin—Ill-defined disorder—Doxorubicin—muscle cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Nervous system disorder—Methotrexate—muscle cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Anaemia—Doxorubicin—muscle cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Thrombocytopenia—Methotrexate—muscle cancer	0.00146	0.00146	CcSEcCtD
Tobramycin—Skin disorder—Methotrexate—muscle cancer	0.00145	0.00145	CcSEcCtD
Tobramycin—Malaise—Doxorubicin—muscle cancer	0.00143	0.00143	CcSEcCtD
Tobramycin—Vertigo—Doxorubicin—muscle cancer	0.00142	0.00142	CcSEcCtD
Tobramycin—Anorexia—Methotrexate—muscle cancer	0.00142	0.00142	CcSEcCtD
Tobramycin—Leukopenia—Doxorubicin—muscle cancer	0.00142	0.00142	CcSEcCtD
Tobramycin—Cough—Doxorubicin—muscle cancer	0.00138	0.00138	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00136	0.00136	CcSEcCtD
Tobramycin—Chest pain—Doxorubicin—muscle cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Myalgia—Doxorubicin—muscle cancer	0.00135	0.00135	CcSEcCtD
Tobramycin—Paraesthesia—Methotrexate—muscle cancer	0.00134	0.00134	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00134	0.00134	CcSEcCtD
Tobramycin—Discomfort—Doxorubicin—muscle cancer	0.00133	0.00133	CcSEcCtD
Tobramycin—Dyspnoea—Methotrexate—muscle cancer	0.00133	0.00133	CcSEcCtD
Tobramycin—Confusional state—Doxorubicin—muscle cancer	0.0013	0.0013	CcSEcCtD
Tobramycin—Decreased appetite—Methotrexate—muscle cancer	0.0013	0.0013	CcSEcCtD
Tobramycin—Anaphylactic shock—Doxorubicin—muscle cancer	0.00129	0.00129	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00129	0.00129	CcSEcCtD
Tobramycin—Pain—Methotrexate—muscle cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Nervous system disorder—Doxorubicin—muscle cancer	0.00127	0.00127	CcSEcCtD
Tobramycin—Thrombocytopenia—Doxorubicin—muscle cancer	0.00126	0.00126	CcSEcCtD
Tobramycin—Skin disorder—Doxorubicin—muscle cancer	0.00125	0.00125	CcSEcCtD
Tobramycin—Anorexia—Doxorubicin—muscle cancer	0.00123	0.00123	CcSEcCtD
Tobramycin—Feeling abnormal—Methotrexate—muscle cancer	0.00123	0.00123	CcSEcCtD
Tobramycin—Gastrointestinal pain—Methotrexate—muscle cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Urticaria—Methotrexate—muscle cancer	0.00119	0.00119	CcSEcCtD
Tobramycin—Abdominal pain—Methotrexate—muscle cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Body temperature increased—Methotrexate—muscle cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00118	0.00118	CcSEcCtD
Tobramycin—Paraesthesia—Doxorubicin—muscle cancer	0.00116	0.00116	CcSEcCtD
Tobramycin—Dyspnoea—Doxorubicin—muscle cancer	0.00115	0.00115	CcSEcCtD
Tobramycin—Decreased appetite—Doxorubicin—muscle cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Pain—Doxorubicin—muscle cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Hypersensitivity—Methotrexate—muscle cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Asthenia—Methotrexate—muscle cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Feeling abnormal—Doxorubicin—muscle cancer	0.00106	0.00106	CcSEcCtD
Tobramycin—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00106	0.00106	CcSEcCtD
Tobramycin—Pruritus—Methotrexate—muscle cancer	0.00106	0.00106	CcSEcCtD
Tobramycin—Urticaria—Doxorubicin—muscle cancer	0.00103	0.00103	CcSEcCtD
Tobramycin—Body temperature increased—Doxorubicin—muscle cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Abdominal pain—Doxorubicin—muscle cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Diarrhoea—Methotrexate—muscle cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Dizziness—Methotrexate—muscle cancer	0.000987	0.000987	CcSEcCtD
Tobramycin—Hypersensitivity—Doxorubicin—muscle cancer	0.000952	0.000952	CcSEcCtD
Tobramycin—Vomiting—Methotrexate—muscle cancer	0.000949	0.000949	CcSEcCtD
Tobramycin—Rash—Methotrexate—muscle cancer	0.000941	0.000941	CcSEcCtD
Tobramycin—Dermatitis—Methotrexate—muscle cancer	0.00094	0.00094	CcSEcCtD
Tobramycin—Headache—Methotrexate—muscle cancer	0.000935	0.000935	CcSEcCtD
Tobramycin—Asthenia—Doxorubicin—muscle cancer	0.000927	0.000927	CcSEcCtD
Tobramycin—Pruritus—Doxorubicin—muscle cancer	0.000914	0.000914	CcSEcCtD
Tobramycin—Nausea—Methotrexate—muscle cancer	0.000886	0.000886	CcSEcCtD
Tobramycin—Diarrhoea—Doxorubicin—muscle cancer	0.000884	0.000884	CcSEcCtD
Tobramycin—Dizziness—Doxorubicin—muscle cancer	0.000854	0.000854	CcSEcCtD
Tobramycin—Vomiting—Doxorubicin—muscle cancer	0.000821	0.000821	CcSEcCtD
Tobramycin—Rash—Doxorubicin—muscle cancer	0.000815	0.000815	CcSEcCtD
Tobramycin—Dermatitis—Doxorubicin—muscle cancer	0.000814	0.000814	CcSEcCtD
Tobramycin—Headache—Doxorubicin—muscle cancer	0.000809	0.000809	CcSEcCtD
Tobramycin—Nausea—Doxorubicin—muscle cancer	0.000767	0.000767	CcSEcCtD
